On January 5, 2021, the invested company Shangke Biopharmaceutical (Shanghai) Co., Ltd. was awarded the "(S)-1-tert-butoxycarbonyl-3-hydroxypiperidine" Shanghai High-tech Achievement Transformation Project. As a national high-tech enterprise, Suntech Biotech always takes biotechnology to lead the development of the chemical and pharmaceutical industry, and brings green and health to human beings as its mission. To expand the business in many ways, actively cooperate with well-known schools and enterprises at home and abroad, constantly develop its own development potential, optimize the internal configuration of the enterprise, and become better and stronger.
Transformation of high-tech achievements
　　The transformation of high-tech achievements refers to the process in which enterprises make high-tech production and function. The state supports enterprises to implement the transformation of scientific and technological achievements through independent research and development, granting licenses, taking shares at a price, and cooperating with industries, universities and research institutes. For the high-tech achievement transformation project reviewed and reported by the enterprise, according to the completion of its comprehensive economic indicators and the attributes and innovation degree of the project's intellectual property rights, its R&D investment is related to the project-related intellectual property rights, invention patent certificates or those entering the substantive examination stage. The certificate of honor issued to the enterprise after strict review and thorough market investigation, such as the certification materials of invention patent application, utility model patent certificate, software copyright registration certificate, integrated circuit layout design registration certificate, etc.
project name:(S)-1-tert-Butoxycarbonyl-3-Hydroxypiperidine    Item Number:202010694    Project class:B   Whether there are achievements in the high-tech field with independent intellectual property rights: Yes
application:(S)-1-tert-Butoxycarbonyl-3-Hydroxypiperidine（CAS：143900-44-1）It is an important chiral intermediate for the synthesis of ibrutinib APIs. Ibrutinib is a new anticancer drug targeting B-cell malignancies that was approved under accelerated approval by the U.S. Food and Drug Administration (FDA) on November 13, 2013 for the treatment of lymphoma.

Company Profile
  

 
      Shangke Biomedical (Shanghai) Co., Ltd. was established in 2008 and is located in the International Medical Park, the southern area of Zhangjiang Hi-Tech Park, Pudong, Shanghai. It is a wholly-owned subsidiary of Zhejiang Shangke Biomedical Co., Ltd. Shangke Bio is committed to the research and development of the most cutting-edge green pharmaceutical field, leads the development of the chemical pharmaceutical industry with green biotechnology, and provides innovative products and high-quality services for the pharmaceutical industry. It is a high-tech enterprise in Shanghai and also a Shanghai "Specialized, refined, special and new" enterprise. Suntech's main business includes: development and application of biological enzymes, development and production of pharmaceutical intermediates, APIs and functional chemicals. The company's main products are coenzyme products, including NMN, NAD, NADP, NADH, NADPH, biological enzymes, pharmaceutical raw materials and intermediates. The company's customers and partners are all over the world, and it has formed close cooperative relations with many pharmaceutical companies in North America, Europe, India and China.